Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6738518 | 0.92 | TSHR (0.96) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL10077130 | 0.91 | L3MBTL1 (0.71) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL3936704 | 0.90 | TSHR (1.00) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL9612077 | 0.90 | TSHR (1.00) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL10726921 | 0.89 | ALDH1A1 (0.74) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL4447317 | 0.89 | TSHR (0.67) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL5127258 | 0.88 | TSHR (0.71) | TSHRHPGDRAB9ANPC1KMT2A | |
| Hydrazine SCHEMBL28119021 | 0.88 | TSHR (0.89) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL656086 | 0.87 | TSHR (0.69) | TSHRHPGDRAB9ANPC1KMT2A | |
| SCHEMBL4608001 | 0.87 | KMT2A (0.85) | TSHRHPGDRAB9ANPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104745007-B | Graphene composite and preparation method thereof | 东进世美肯株式会社 | 2022-01-18 | — | — | CN | claimed |
| CN-104745007-A | GRAPHENE COMPOSITE AND METHOD FOR PREPARING THE SAME | DONGJIN SEMICHEM CO LTD | 2015-07-01 | — | — | CN | claimed |
| CN-117417343-A | Synthetic method of natural products Pancratinine B and C | 华中科技大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-117417342-A | Synthetic method of natural products Pancratinine B and C | 华中科技大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-113754674-B | Synthetic method of natural products Pancratinine B and C | 华中科技大学 | 2023-11-28 | — | — | CN | disclosed |
| CN-113637009-B | Method for preparing aza-heterocyclic compound | 华中科技大学 | 2023-03-28 | — | — | CN | disclosed |
| CN-104745007-B | Graphene composite and preparation method thereof | 东进世美肯株式会社 | 2022-01-18 | — | — | CN | disclosed |
| US-9994443-B2 | Modified nicotinic compounds and related methods | SELECTA BIOSCIENCES, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| CN-104745007-A | GRAPHENE COMPOSITE AND METHOD FOR PREPARING THE SAME | DONGJIN SEMICHEM CO LTD | 2015-07-01 | — | — | CN | disclosed |
| EP-2640190-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | Selecta Biosciences, Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| CN-102702044-A | Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors | SCHERING CORP | 2012-10-03 | — | — | CN | disclosed |
| WO-2012061717-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | SELECTA BIOSCIENCES, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120114677-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | SELECTA BIOSCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| US-8138272-B2 | Preparation of polymer conjugates of therapeutic, agricultural, and food additive compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| CN-101495152-A | Preparation of polymer conjugates of vla-4 antagonists via a mitsunobu' s reaction | ELAN PHARM INC (US) | 2009-07-29 | — | — | CN | disclosed |
| EP-2019690-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU'S REACTION | Elan Pharmaceuticals Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | ELAN PHARMACEUTICALS, INC. | 2008-02-07 | — | — | US | disclosed |
| WO-2007137260-A2 | PREPARATION OF POLYMER CONJUGATES OF VLA-4 ANTAGONISTS VIA A MITSUNOBU' S REACTION | ELAN PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080031848-A1 | Preparation of Polymer Conjugates of Therapeutic, Agricultural, and Food Additive Compounds | PIGO, MANBA, OAT | TSHR 2205/4885HPGD 1728/4885RAB9A 2191/4885 |
| US-20120114677-A1 | MODIFIED NICOTINIC COMPOUNDS AND RELATED METHODS | NNMT, CHRNG, CHRM5 | TSHR 2185/4885HPGD 800/4885RAB9A 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.